Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC).
• Brain metastases are common in NSCLC patients, particularly those with non-classical EGFR mutations like exon 20 insertions.
• Non-classical EGFR mutations present a significant unmet medical need due to poorer prognosis.

Purpose of the Study:

• To describe the discovery and development of enozertinib (ORIC-114), a novel EGFR inhibitor.
• To evaluate enozertinib's efficacy against EGFR exon 20 insertions and other atypical mutations.
• To assess enozertinib's brain penetrance and therapeutic potential in NSCLC with brain metastases.

Main Methods:

• Discovery and preclinical development of enozertinib, an orally bioavailable, irreversible EGFR inhibitor.
• In vitro and in vivo studies assessing enozertinib's potency and tumor regression in atypical EGFR mutant models.
• Phase I clinical trial evaluating enozertinib in advanced NSCLC patients with atypical EGFR mutations.

Main Results:

• Enovertinib demonstrated strong potency and significant tumor regressions across various atypical EGFR mutant models.
• The drug exhibited high kinome selectivity, specifically targeting EGFR exon 20 mutations.
• A patient with EGFR exon 20 insertion achieved a sustained complete response of systemic and brain metastases in a Phase I trial.

Conclusions:

• Enovertinib is a potent, brain-penetrant inhibitor targeting EGFR exon 20 insertions and other atypical mutations.
• The drug shows significant promise for treating NSCLC patients with brain metastases and EGFR exon 20 insertions.
• Enovertinib represents a potential new therapeutic option for a high unmet need population in NSCLC.